Wednesday, September 23, 2026
RSS

Inside BCI

Brain-Computer Interface Industry News
Industry News Research Policy Opinion Market Moves
About Directory Glossary
Market Moves

BCI-Sonics closes RMB 200 million Pre-A led by HongShan and Yunqi Partners

Shanghai-headquartered non-invasive brain-computer interface company BCI-Sonics closed a RMB 200 million (~USD 28 million) Pre-A financing round on Tuesday 22 September 2026, co-led by HongShan (the post-2023 rebrand of Sequoia China under Neil Shen) and Yunqi Partners. New participants included Proxima Capital, Oriza Holdings, Shanghai's Xuhui Sci-Tech Innovation Investment, and Moral Stone Investment. Existing investors Matrix Partners China (MPCi) and Delian Capital followed on. Xunguang Capital served as exclusive financial advisor. Total capital raised since 2025 founding is roughly RMB 300 million. The company was founded by Dr. Li Xin, formerly Head of GE Global Research Center China and a joint PhD graduate of the Chinese Academy of Sciences and Fraunhofer IGD in Germany. BCI-Sonics' modality is low-intensity transcranial focused ultrasound (tFUS/LIFU) for brain stimulation, paired with a multimodal reading system combining functional ultrasound (fUS), EEG, fMRI and PET, and passive cavitation detection for safety monitoring. Three product lines are in development: a Research toolchain for neuroscience labs (unveiled at CNS 2026 in September), a Clinical portfolio targeting pain, Parkinson's, Alzheimer's, addiction, sleep, and ultrasound-mediated blood-brain-barrier opening for CNS drug delivery, and a Technology/Consumer wearable BCI terminal for sleep, focus and emotion. Closed-loop ultrasound BCI clinical trials are scheduled to enter Q1 2027. The Pre-A closed the same day Premier Li Qiang inspected BCI products in Shanghai and directed the establishment of future-industry investment-growth and risk-sharing mechanisms and 'patient capital' (耐心资本) expansion.

Sep 24, 2026 · 7 min read

Policy & Regulation

Chinese Premier Li Qiang publicly names brain-computer interfaces a 'blue ocean' on a Shanghai inspection tour

China's Premier Li Qiang, a member of the Politburo Standing Committee, spent Tuesday 22 September 2026 on a Shanghai inspection tour of two innovation venues. At the second, the Shanghai Future Kick-off Community (上海未来启点社区) sci-tech innovation and incubation platform for future industries, he inspected technology products in two named categories: brain-computer interfaces and quantum computing. He then framed future industries as 'a potential blue ocean for advanced manufacturing' (先进制造业发展的潜在蓝海). Shanghai Party Secretary Chen Jining and State Council Secretary-General Wu Zhenglong accompanied the tour. The remarks operationalise General Secretary Xi Jinping's prior directive on advanced manufacturing and the spirit of the National Conference on Advanced Manufacturing. The visit lands Li Qiang's on-record inspection of BCI products above the March 2025 Government Work Report first-mention (re-named March 2026), above the 15th Five-Year Plan naming of BCI as a future industry (CPC 4th Plenum, 20 to 23 October 2025), and above the seven-ministry BCI Implementation Opinions of 20 July 2025. The venue itself is not disclosed to have featured named Chinese BCI operators. Shanghai's Minhang District already hosts the country's first BCI industry cluster at Brain Intelligence World, which by mid-2026 housed 61 BCI companies, roughly 30 percent of the national BCI operator field.

Sep 23 · 6 min read

Industry News

Neuralink discloses direct thought-to-audio speech decoding in ALS participant Terry, the VOICE trial's third implantee

Neuralink published a video this week showing Terry, a married man with bulbar-onset ALS, saying 'Hello, how are you doing today?' and 'I, I love you' to his wife through an implanted N1 brain-computer interface. The output routed through Grok Voice, xAI's speech engine, using a clone of Terry's own pre-ALS recordings. It is Neuralink's most detailed publicly disclosed thought-to-speech demonstration to date and the first to route through xAI's Grok Voice engine for personalised voice synthesis. Another VOICE participant, Kenneth Shock, appeared in a Neuralink clip on 16 September 2026, two days before Terry's disclosure, saying 'I love you' to his wife. Terry is the third participant in Neuralink's VOICE early-feasibility trial (ClinicalTrials.gov NCT07224256), formally titled 'VOICE: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for Communication Restoration.' VOICE is a separate protocol from Neuralink's PRIME motor-decoding trial and its CAN-PRIME and GB-PRIME international arms. The N1 implant holds an FDA Breakthrough Device Designation; it is not FDA-approved and not commercially available. Prior Neuralink participants Noland Arbaugh (PRIME P1), Alex (PRIME P2), and Brad Smith (PRIME first ALS participant) are on the motor decoding track. Brad Smith's earlier speech restoration used cursor-typed text through a cloned voice; Terry's demonstration is the first Neuralink disclosure of direct neural-to-audio decoding. Neuralink has not published words-per-minute, word-error-rate, latency, or vocabulary-size metrics. No peer-reviewed methods paper accompanies the demonstration.

Sep 23 · 5 min read

Industry News

Science Corporation names Darius Shahida President as PRIMA retinal implant enters commercial rollout

Science Corporation, Max Hodak's Alameda-headquartered neural engineering and brain-computer interface company, announced on 17 September 2026 that Chief Strategy Officer Darius Shahida has been appointed President in a dual role. Shahida joined full-time in January 2026 as CSO after eight years at Butterfly Network and after first participating in Science's Series B as an investor. He is the second senior Butterfly Network alumnus hired by Science this year; Nevada Sanchez, a Butterfly Network co-founder, joined as EVP Engineering on 29 July 2026. The Shahida appointment lands two months into the European commercial rollout of PRIMA, Science's photovoltaic subretinal implant for geographic atrophy in age-related macular degeneration, which received CE mark from DEKRA in July 2026 (30 European countries; commercial launch also covers the UK) and simultaneous FDA Breakthrough Device and Humanitarian Use Device designations. Science closed a $230 million Series C on 5 March 2026 from Khosla Ventures, Lightspeed, Y Combinator, IQT, Quiet Capital and others, bringing total capital raised to roughly $490 million since founding in 2021. Hodak remains CEO. The company operates from Alameda with offices in Paris and Research Triangle Park.

Sep 19 · 5 min read

Industry News

Arbor Neuroscience CEO Philip Sabes tells Shanghai BCI symposium that prediction is the neuromodulation bottleneck

Philip Sabes, a Neuralink co-founder (full-time 2017 to 2020) and now CEO of Arbor Neuroscience, delivered a keynote at the BCI Inno+ Salon International Symposium on Brain-Computer Interface in Shanghai on 14 September 2026. His stated thesis was that the real bottleneck in neuromodulation is prediction: because clinicians cannot reliably predict what will happen after brain stimulation, treatment outcomes are inconsistent. Sabes summarised current practice as 'poke and hope' and positioned Arbor's approach as 'predict and treat'. Arbor Neuroscience is the September 2026 rebrand of Forest Neurotech, a functional-ultrasound-imaging Focused Research Organization founded by Sumner Norman, Tyson Aflalo and Will Biederman inside Convergent Research. The symposium was hosted by the BCI Innovation and Transformation Center at Brain Intelligence World in Shanghai's Minhang District, a Shanghai state-backed partnership between Minhang District, Lingang Group, Shanghai State Investment Corp and Huashan Hospital (a Fudan University teaching hospital), positioned as China's first BCI industry cluster. Sabes made no public statement on US and China BCI competition, export controls, or the recent NSCEB and BIS enforcement actions.

Sep 19 · 4 min read

Research

UCSF brain-computer interface decodes speech and body gestures simultaneously from a single cortical implant

A Nature Neuroscience paper published on 14 September 2026 by Samantha C. Brosler, Jessie R. Liu, Alexander B. Silva and senior author Edward F. Chang at UCSF reports the first single-implant, single-session, real-time simultaneous decoding of speech and upper-body gestures in people with paralysis. Two of three BRAVO-trial participants (Bravo-1r, brainstem stroke, seven years enrolled; Bravo-6, ALS, implanted March 2025) controlled a personalized virtual avatar with parallel speech and gesture decoders reading from a 253-channel high-density ECoG surface array manufactured by PMT Corporation. Bravo-1r reached median 100 percent accuracy on both decoders in the real-time conversation paradigm; Bravo-6 reached 85 percent gesture and 75 percent speech. The design finding is that multimodal neural signals are not the linear sum of isolated speech and gesture signals: decoders trained on simultaneous data outperform decoders trained on isolated data, and cross-training drops opposite-modality false-positive rates from 76 percent (Bravo-1r) and 31 percent (Bravo-6) to zero. Chang has stated a fully implantable wireless successor is the next step. Hardware footprint is PMT surface ECoG plus a Blackrock Neurotech digital headstage per prior Chang-lab methods, with no overlap with Neuralink Threads, Paradromics Connexus, or Synchron Stentrode. This is the fourth UCSF Chang-lab BRAVO paper in the peer-reviewed communication-BCI sequence: Moses NEJM 2021, Metzger Nature 2023, Littlejohn Nature Neuroscience 2025, Brosler Nature Neuroscience 2026.

Sep 18 · 6 min read

Policy & Regulation

China issues a medical-device standard for AI processing of EEG data in brain-computer interfaces

China's National Medical Products Administration (NMPA) has issued what state news agency Xinhua characterises as the world's first medical-device standard covering AI-processed electroencephalogram (EEG) data in brain-computer interfaces, announced on 14 September 2026. The standard was drafted by the National Institutes for Food and Drug Control (NIFDC) under an expedited procedure and becomes effective on 1 September 2027. Scope: quality requirements and evaluation methods for EEG datasets used by AI algorithms in BCI medical devices, covering collection, processing, annotation, storage, and access across R&D, production, and quality-control stages. Named NMPA and NIFDC officials: Yuan Peng (Deputy Director, NMPA Department of Medical Device Registration), Li Shu (Deputy Director, NIFDC medical device institute), Zheng Jia (Deputy Director, NIFDC Institute for Medical Device Standardization). This is the third BCI-related medical-device standard issued by China in twelve months, following 2025 standards on BCI terminology and on test methods for implantable closed-loop neural stimulators. The US FDA has no BCI-specific AI/EEG data-quality standard. The EU has no BCI-specific standard, only horizontal AI Act coverage of medical BCI as high-risk. On the narrow AI-EEG-BCI slice, China's world-first framing holds up.

Sep 17 · 8 min read

Industry News

Paradromics's first Connexus participant used a brain implant to speak her own words

Paradromics announced on 14 September 2026 that the first participant in its Connect-One Early Feasibility Study, a Michigan woman in her 60s with progressive motor neuron disease and severe dysarthria, has used the Connexus intracortical brain-computer interface to generate her own words, answer open-ended questions, and hold a live phone call with her grandchildren, three months after her June 2026 implant at University of Michigan Health. Verbatim first sentence: 'Okay, I have a lot to say.' Second sentence: 'Don't be afraid. It's a wonderful experience to be able to help others by your participation in the research study.' Both were decoded in real time, word for word, with no errors, according to Paradromics. Output modality is text plus synthesized speech (not avatar-mediated). Quantitative benchmarks (words per minute, word-error rate, vocabulary size, decoding latency) were not disclosed. The Connect-One EFS runs across three sites (University of Michigan Health, UC Davis Health, Mass General Brigham) under FDA IDE approval granted in November 2025. Same-day academic milestone at UCSF (Edward Chang team, Nature Neuroscience) demonstrates simultaneous speech and gesture decoding via animated avatar. The two results are categorically different (commercial vs academic, text-plus-audio vs avatar-mediated) and should not be conflated.

Sep 16 · 8 min read

Market Moves

Three Chinese BCI operators are in the IPO queue at once

Three Chinese brain-computer interface operators are simultaneously moving through IPO processes on two exchanges. Neuracle Medical Technology (博睿康技术（上海）股份有限公司) is the leader: its Shanghai STAR Market prospectus was accepted 11 June 2026 with a planned RMB 2.5 billion (~US$345M) raise. Neuracle received China's first commercial invasive BCI approval from NMPA in March 2026 (NEO-ONE SCI for spinal cord injury). BrainCo (强脑科技) filed a confidential Hong Kong Exchange application in January 2026 (joint sponsors CICC and UBS), with the September 2026 pricing calendar showing no imminent hearing. Arfysica Innovation (术理创新), led by female founder Wang Wei, registered STAR Market pre-IPO tutoring in early September 2026 with Huatai United Securities, entering the pipeline three months behind Neuracle at the earliest stage. Neuracle's disclosed prospectus reveals RMB 108 million 2025 revenue, all from non-invasive EEG systems, with the NEO invasive product still at zero commercial revenue and 32 patients implanted by end-2025.

Sep 14 · 10 min read